cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination

被引:942
作者
Bertrand, Mathieu J. M. [1 ]
Milutinovic, Snezana [1 ]
Dickson, Kathleen M. [1 ]
Ho, Wai Chi [1 ]
Boudreault, Alain [2 ]
Durkin, Jon [2 ]
Gillard, John W. [2 ]
Jaquith, James B. [2 ]
Morris, Stephen J. [2 ]
Barker, Philip A. [1 ]
机构
[1] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada
[2] Aegera Therapeut Inc, Ile De Soeurs, PQ H3E 1A8, Canada
关键词
D O I
10.1016/j.molcel.2008.05.014
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The inhibitor of apoptosis (IAP) family of proteins enhances cell survival through mechanisms that remain uncertain. In this report, we show that cIAP1 and cIAP2 promote cancer cell survival by functioning as E3 ubiquitin ligases that maintain constitutive ubiquitination of the RIP1 adaptor protein. We demonstrate that AEG40730, a compound modeled on BIR-binding tetrapeptides, binds to cIAP1 and cIAP2, facilitates their autoubiquitination and proteosomal degradation, and causes a dramatic reduction in RIP1 ubiquitination. We show that cIAP1 and cIAP2 directly ubiquitinate RIP1 and induce constitutive RIP1 ubiquitination in cancer cells and demonstrate that constitutively ubiquitinated RIP1 associates with the prosurvival kinase TAK1. When deubiquitinated by AEG40730 treatment, RIP1 binds caspase-8 and induces apoptosis. These findings provide insights into the function of the IAPs and provide new therapeutic opportunities in the treatment of cancer.
引用
收藏
页码:689 / 700
页数:12
相关论文
共 31 条
[1]   The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases [J].
Eckelman, BP ;
Salvesen, GS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (06) :3254-3260
[2]   RIP1, a kinase on the crossroads of a cell's decision to live or die [J].
Festjens, N. ;
Vanden Berghe, T. ;
Cornelis, S. ;
Vandenabeele, P. .
CELL DEATH AND DIFFERENTIATION, 2007, 14 (03) :400-410
[3]   A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-α signaling [J].
Gaither, Alex ;
Porter, Dale ;
Yao, Yao ;
Borawski, Jason ;
Yang, Guang ;
Donovan, Jerry ;
Sage, David ;
Slisz, Joanna ;
Tran, Mary ;
Straub, Christopher ;
Ramsey, Tim ;
Iourgenko, Vadim ;
Huang, Alan ;
Chen, Yan ;
Schlegel, Robert ;
Labow, Mark ;
Fawell, Stephen ;
Sellers, William R. ;
Zawel, Leigh .
CANCER RESEARCH, 2007, 67 (24) :11493-11498
[4]   Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-κB [J].
Habelhah, H ;
Takahashi, S ;
Cho, SG ;
Kadoya, T ;
Watanabe, T ;
Ronai, Z .
EMBO JOURNAL, 2004, 23 (02) :322-332
[5]   Characterization of XIAP-deficient mice [J].
Harlin, H ;
Reffey, SB ;
Duckett, CS ;
Lindsten, T ;
Thompson, CB .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (10) :3604-3608
[6]   Inhibitor of apoptosis 2 and TAK1-binding protein are components of the Drosophila Imd pathway [J].
Kleino, A ;
Valanne, S ;
Ulvila, J ;
Kallio, J ;
Myllymäki, H ;
Enwald, H ;
Stöven, S ;
Poidevin, M ;
Ueda, R ;
Hultmark, D ;
Lemaitre, B ;
Rämet, M .
EMBO JOURNAL, 2005, 24 (19) :3423-3434
[7]   The kinase activity of Rip1 is not required for tumor necrosis factor-α-induced IκB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2 [J].
Lee, TH ;
Shank, J ;
Cusson, N ;
Kelliher, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (32) :33185-33191
[8]   Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation [J].
Legler, DF ;
Micheau, O ;
Doucey, MA ;
Tschopp, J ;
Bron, C .
IMMUNITY, 2003, 18 (05) :655-664
[9]   The Drosophila inhibitor of apoptosis protein DIAP2 functions in innate immunity and is essential to resist gram-negative bacterial infection [J].
Leulier, Francois ;
Lhocine, Nouara ;
Lemaitre, Bruno ;
Meier, Pascal .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (21) :7821-7831
[10]   Ubiquitination of RIP is required for tumor necrosis factor α-induced NF-κB activation [J].
Li, HX ;
Kobayashi, M ;
Blonska, M ;
You, Y ;
Lin, X .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (19) :13636-13643